Cerebral vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Online mental health platform for therapy, medication management, and psychiatry, San Francisco CA, raised $300M+. Serves anxiety, depression, ADHD, and insomnia.
About
Cerebral is a San Francisco, California-based online mental health company founded in 2020 that offers therapy, psychiatric evaluations, and medication management through a telehealth platform. The company raised over $300 million, achieving unicorn status in 2021 during a period of rapid growth, and serves patients with conditions including anxiety, depression, ADHD, insomnia, and bipolar disorder through a subscription-based access model.\n\nCerebral's model is designed to make psychiatric care and therapy more accessible than traditional in-person services by offering online intake, same-week appointments with licensed clinicians, electronic prescriptions, and medication delivery through pharmacy partners. The platform serves both self-pay and insurance-covered patients, having expanded insurance contracting significantly to reduce cost barriers. Cerebral employs a large clinician workforce of therapists and psychiatric nurse practitioners operating across most US states.\n\nThe company navigated a period of regulatory and reputational scrutiny in 2022–2023 related to prescribing practices and marketing claims, which led to leadership changes, workforce restructuring, and a strategic refocus on clinical quality and compliance. Cerebral has since invested in clinical governance infrastructure, stricter prescribing protocols, and transparent outcomes reporting. The company continues to compete with Talkspace, Done, and Done Global in the online psychiatry and therapy market, and has repositioned around a more clinically rigorous, insurance-first approach following the operational challenges of its hypergrowth phase.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.